UroToday- The search continues for serum markers that predict outcomes in patients with renal cell carcinoma (RCC). C-reactive protein (CRP) is an acute phase reactant found in serum that is frequently increased in patients with cancer. Here Komai and colleagues examine CRP levels as a predictor of outcome in patients with localized RCC.

The authors examined the serum level of CRP in 101 patients with localized RCC (T1-T3N0M0), where an elevated CRP was defined as >0.5 mg/dl prior to surgery. With a median follow-up of 55 months (range 2-187), 26% of patients were found to have elevated levels of CRP. The 5 and 10 year disease specific survival (DSS) for patients with an elevated CRP was 75% and 30%, respectively, whereas the 5 and 10 year DSS for patients with a normal CRP was 93% at both time points (p

Tag Cloud